Opioid Overdose – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Opioid Overdose Market Outlook
Thelansis’s “Opioid Overdose Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Opioid Overdose treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Opioid
Overdose Overview
The term
“opioids” encompasses compounds derived from the poppy plant (Papaver
somniferum), along with semisynthetic and synthetic counterparts sharing
similar properties that can engage with opioid receptors in the brain. Opioids,
such as morphine, codeine, and fentanyl, are commonly employed for pain
management due to their analgesic and sedative effects. Medications like
methadone and buprenorphine are used for the maintenance treatment of opioid
dependence. Upon ingestion, opioids can induce euphoria, a primary motivator
for their non-medical use. This category includes substances like heroin,
tramadol, and others. Owing to their pharmacological impact, opioids can pose
risks to respiratory function, and an opioid overdose can result in fatality.
Three indicative signs of an opioid overdose include pinpoint pupils,
unconsciousness, and breathing difficulties. An opioid overdose transpires when
there is an excessive, unopposed stimulation of the opiate pathway, leading to
diminished respiratory effort and potential death. The incidence of opioid
overdose is on the rise. Opioids operate by acting as potent agonists to the mu
receptor within the endogenous opioid system, triggering a complex cascade of
signals that involve dopamine release, pain signal blockade, and the emergence
of euphoria. Opioid receptors are distributed in the brain, spinal cord, and
gut. During an overdose, an exaggerated impact on the brain’s respiratory rate
regulation can result in respiratory depression and, ultimately, death.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment